SESSION TITLE: Novel Methods for Lung Cancer Diagnosis
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Tuesday, October 25, 2016 at 08:45 AM - 09:45 AM
PURPOSE: Currently, risk stratifying a lung nodule is clinically and imaging based, but several commercial blood tests are now available to facilitate management independently. In our clinical lung nodule program, we are studying the performance of two of these tests. Xpresys® uses mass spectrometry to analyze 5 plasma proteins that classifies a lung nodule as either likely benign or indeterminate and is designed to “rule-out” cancer. EarlyCDT-lung® is an ELISA assay that measures 7 auto-antibodies, which stratifies risk into low, moderate or high and is designed to “rule-in” lung cancer.